BioPharma Resources

Drug Trial Radar · NCT06935357

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 454 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

454

Planned (sponsor's estimate)

Start

May 8, 2025

Primary completion

May 31, 2027

Study completion Jun 5, 2029

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Apr 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caused by the buildup of an antibody called IgA in the kidneys over time. In people with IgAN, abnormal IgA and other antibodies form clusters that build up in the small filters of the kidneys, which leads to inflammation and damage. Felzartamab is designed to target certain immune cells that produce these abnormal antibodies. This study will focus on participants who have protein in their urine (proteinuria) as a result of damaged kidneys. The main goal of the study is to learn about the effect felzartamab has on proteinuria. The main question that researchers want to answer is: • How much does the amount of protein in the urine change from the start of the study to Week 36? Researchers will learn about the effect felzartamab has on the kidneys' ability to filter blood. They will also learn more about the safety of felzartamab and how it is processed by the body. The study will be done as follows: * Participants will be screened to check if they can join the study. * Participants will be randomized to receive either felzartamab or a placebo. A placebo looks like the study drug but contains no real medicine. * Neither the researchers nor the participants will know what the participants will receive. * Participants will receive felzartamab or placebo as intravenous (IV) infusions. The treatment period will last 24 weeks. * Afterwards, participants will enter a follow-up period which will last 80 weeks. * In total, participants will have 17 study visits. Participants will stay in the study for about 2 years.

Conditions

  • Immunoglobulin A Nephropathy (IgAN)

Interventions

  • FelzartamabDrug

    Administered IV

  • PlaceboDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Proteinuria as Measured by the Urine Protein: Creatinine Ratio (UPCR)Time frame: Baseline up to Week 36

Locations

265 sites in 28 countries. Site status is shown where the registry gives one.

  • Applied Research Center of Arkansas

    Little Rock, Arkansas · Recruiting

  • Kidney & Hypertension Center - Apple Valley

    Apple Valley, California · Recruiting

  • Scripps Green Hospital

    Carlsbad, California · Recruiting

  • National Institute of clinical Research Administration Office

    Garden Grove, California · Withdrawn

  • UCLA Health David Geffen School of Medicine

    Los Angeles, California · Recruiting

  • FOMAT Medical Research - FOMAT - PPDS

    Oxnard, California · Recruiting

  • North America Research Institute-San Dimas

    San Dimas, California · Recruiting

  • Nova Clinical Research, LLC

    Bradenton, Florida · Recruiting

  • University of Florida - Gainesville - 1600 SW Archer Rd

    Gainesville, Florida · Recruiting

  • Royal Research, Corp.

    Hollywood, Florida · Recruiting

  • Central Florida Kidney Specialists

    Orlando, Florida · Recruiting

  • CDC Research Institute, LLC

    Port Saint Lucie, Florida · Recruiting

  • American Clinical Trials LLC

    Acworth, Georgia · Withdrawn

  • The Vasculitis and Glomerulonephritis Center at Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • UMass Memorial Medical Center

    Worcester, Massachusetts · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Elixia Health - Michigan Kidney Consultants, LLC - Elixia - PPDS

    Pontiac, Michigan · Withdrawn

  • Anointed Nephrology and HTN - SKYCRNG - PPDS

    Brookhaven, Mississippi · Recruiting

  • Midwest Nephrology Associates,Inc.

    City of Saint Peters, Missouri · Withdrawn

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • James J Peters Veterans Administration Medical Center - NAVREF - PPDS

    The Bronx, New York · Recruiting

  • Penn Renal Electrolyte and Hypertension Perelman

    Philadelphia, Pennsylvania · Not yet recruiting

  • Lifespan at Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • Knoxville Kidney Center, PLLC

    Knoxville, Tennessee · Recruiting

  • Texas Kidney Institute - Dallas

    Dallas, Texas · Recruiting

  • Provecta Research Network

    Houston, Texas · Recruiting

  • R & H Clinical Research

    Katy, Texas · Recruiting

  • Medical College of Wisconsin, Inc.

    Milwaukee, Wisconsin · Recruiting

  • Consultorios Médicos Dr. Doreski - Fundacion Respirar - PPDS

    Buenos Aires, Argentina · Recruiting

  • DOM Centro de Reumatología

    Buenos Aires, Argentina · Recruiting

  • Maffei Centro Médico

    Buenos Aires, Argentina · Not yet recruiting

  • Clínica de Nefrología Urología Y Enfermedades Cardiovasculares

    Santa Fe, Argentina · Recruiting

  • Hospital General de Agudos Dr. Cosme Argerich

    La Boca, Buenos Aires F.D., Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    Almagro, Ciudad Autónoma de BuenosAires, Argentina · Recruiting

  • INECO Neurociencias Oroño

    Rosario, Santa Fe Province, Argentina · Recruiting

  • CIMER-Centro Integral de Medicina Respiratoria

    San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting

  • John Hunter Hospital

    New Lambton, New South Wales, Australia · Recruiting

  • Concord Repatriation General Hospital

    New South Wales, New South Wales, Australia · Recruiting

  • Royal North Shore Hospital-Reserve Road

    St Leonards, New South Wales, Australia · Recruiting

Showing 40 of 265 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.